Literature DB >> 20360041

Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis.

Cécile Escalas1, Sophie Trijau, Maxime Dougados.   

Abstract

OBJECTIVES: To assess the treatment effect of NSAIDs and TNF blockers in AS according to different domains of interest.
METHODS: A systematic literature research was performed in electronic databases up to October 2009. All randomized controlled trials (RCTs) reporting the efficacy (on pain and/or physical function and/or acute-phase reactants) of NSAIDs/anti-TNF vs placebo in AS were selected. Pooled effect sizes were calculated by meta-analysis, using fixed or random-effect models.
RESULTS: Optimal data to calculate the effect size were available in 8 out of the 240 selected RCTs evaluating anti-TNF and 5 of the 135 evaluating NSAIDs. For the domains pain, physical function and patient's global assessment, the treatment effect was large or medium for both TNF blockers and NSAIDs. For the domain acute-phase reactants, the effect of TNF blockers was medium [standardized mean difference (SMD) (95% CI) -0.56 (-0.70, -0.42)], whereas NSAIDs had no significant effect on acute-phase reactants {SMD [95% odds ratio (OR)] -0.09 (-0.34, 0.16)}. Finally for the domain mobility, the effect of both TNF blockers and NSAIDs was small and not significant.
CONCLUSION: This study suggests that the treatment effect of NSAIDs and anti-TNF are both of relevant magnitude considering the main patient-reported outcomes but with a trend in favour of anti-TNF despite the fact that such drugs are given on top of NSAIDs in refractory patients. Moreover, a statistically significant difference was observed for the domain 'acute-phase reactants' confirming the specificity of such drug category.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20360041     DOI: 10.1093/rheumatology/keq078

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  12 in total

Review 1.  Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies.

Authors:  Nurullah Akkoc; Gercek Can; Salvatore D'Angelo; Angela Padula; Ignazio Olivieri
Journal:  Curr Rheumatol Rep       Date:  2017-02       Impact factor: 4.592

2.  The association of NLRP3 and TNFRSF1A polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept.

Authors:  Shengchun Zhao; Hongwei Chen; Guolin Wu; Chen Zhao
Journal:  J Clin Lab Anal       Date:  2017-01-23       Impact factor: 2.352

3.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].

Authors:  U Kiltz; J Sieper; H Kellner; D Krause; M Rudwaleit; J-F Chenot; A Stallmach; S Jaresch; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

Review 4.  [Current treatment of axial spondylarthritis : Clinical efficacy].

Authors:  U Kiltz; J Braun
Journal:  Z Rheumatol       Date:  2020-02       Impact factor: 1.372

5.  Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis.

Authors:  Min Jung Kim; Eunyoung Emily Lee; Eun Young Lee; Yeong Wook Song; Hyeong Gon Yu; Yunhee Choi; Eun Bong Lee
Journal:  Clin Rheumatol       Date:  2018-08-04       Impact factor: 2.980

6.  Bushen-Qiangdu-Zhilv decoction inhibits osteogenic differentiation of rat fibroblasts by regulating connexin 43.

Authors:  Ying-Yan Zhou; Run-Yue Huang; Jie-Hua Lin; Yong-Yue Xu; Xiao-Hong He; Yi-Ting He
Journal:  Exp Ther Med       Date:  2016-04-26       Impact factor: 2.447

Review 7.  Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.

Authors:  Marina Amaral de Ávila Machado; Mariana Michel Barbosa; Alessandra Maciel Almeida; Vânia Eloisa de Araújo; Adriana Maria Kakehasi; Eli Iola Gurgel Andrade; Mariangela Leal Cherchiglia; Francisco de Assis Acurcio
Journal:  Rheumatol Int       Date:  2013-05-18       Impact factor: 2.631

8.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

Review 9.  Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.

Authors:  Francesco Caso; Luisa Costa; Antonio Del Puente; Matteo Nicola Dario Di Minno; Gelsy Lupoli; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

Review 10.  Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).

Authors:  Féline P B Kroon; Lennart R A van der Burg; Sofia Ramiro; Robert B M Landewé; Rachelle Buchbinder; Louise Falzon; Désirée van der Heijde
Journal:  Cochrane Database Syst Rev       Date:  2015-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.